## **Supporting Information**

## **Inhibitors of p21-Activated Kinases (PAKs)**

Joachim Rudolph, † James J. Crawford, † Klaus P. Hoeflich, \* Weiru Wang

<sup>†</sup>Discovery Chemistry, <sup>‡</sup>Structural Biology, Genentech, 1 DNA Way, South San Francisco, CA, United States

Detailed kinase selectivity data of compounds 5, 7, 13, 25, and 28.

<sup>\*</sup>Department of Biology, Blueprint Medicines, 215 First Street, Cambridge, MA, United States

Detailed kinase selectivity data of compounds 5, 7, 13, 25, and 28 (1 of 3); Source: Invitrogen.

Compound	5	7	13	25	28	Compound	5	7	13	25	28
Test concentration [uM]	1	1	0.1	1	0.1	Test concentration [uM]	1	1	0.1	1	0.1
ACVR1B	1.5	71.3	-0.1	-7	79.3	DCAMKL2			10.9	23.1	
ACVR2B				-1.4		DDR1				38	
AKT1	18.5	2	1.1	-1.7	3.3	DMPK				0.4	
AKT2	-17	7	3.6	8.1		DNA-PK			-6.3	6	
ALK2				6.8		DRAK1				-4.4	
ARK5	95.5	67		60	85.5	DYRK1A	6	3	-2	4.1	
ASK1				47.2		DYRK1B	7	0	0.5	1	
Abl	57.5	98	-0.2	15	99.5	DYRK3	6	-0.6	0.9	2	3.8
Arg	77	98	10.2	7	95.3	DYRK4			-3	1.4	
Aurora A	62.3	60	10.3	7.3	25.9	EGFR	4.5	62.3	2.4	-0.6	38
Aurora B	20	42	4.7	22.4	20.0	ERK1	20	6	6.2	5.4	12.3
Axl	67	13	1.9	16.5		ERK2	20	1	5	5.4	
B-Raf	35.5	65	8.2	11.9	49	EphA1	1.7	101	15	86.1	90.7
B-Raf(V599E)	20	73	0.2	33	45	EphA2	18	93	9.8	18	43.5
BMPR1A	20	13		-0.9		EphA3				1.2	
BTK	72.5	84.7	0.8	5.8	86.3	EphA7				7.5	
Blk	79	94	7.2	26.4	86	EphA8			0	65.2	
	66	97	11.6	15.4	91.5	EphB1	19.1	96	100.1	74.5	93
Bmx BrSK1	00	31	4.6	8.6	51.5	EphB3			5.5	7.2	
	F F	00.5			00.5	EphB4	15	96.5	5.3	30.6	78.9
Brk	5.5	96.5	10.2	71.7	92.5	ErbB2	4	40	-5	2.4	
CAMKK1				0.3		ErbB4	2	84	-1	1.6	78.9
CAMKK2				-2.1	40.5	FAK	38	32	3.5	6.8	
CDK1/cyclinB	7.5	4	8.1	4.4	16.5	FGFR1	82	91.5	-4.5	16.9	83
CDK2/cyclinA	22	0	1.9	-8.1		FGFR2	72	93	6.8	15	55.6
CDK5/p25	18	0	4.3	4.4		FGFR3	31	68	7.6	0.5	45.5
CDK5/p35	17	-1	-1.6	0		FGFR4	11	39	-1	4.7	
CDK7/cyclinH	98	6		-1.4	31	Fes	43	93.5	51	38.7	38.3
CDK8/cyclinC	3	11.5		12.4	57.3	Fgr			3.6	10.1	
CDK9/cyclinT1	13	-1		-3.3		Flt1	6	58.7	-6	10.8	18.6
CHK1	91.4	3	-3.5	-8.8	19.1	Flt3	77.4	92.3	8.7	24.9	83.4
CHK2	99	7	5.1	3.6	4.3	Flt4			1	33.5	
CK1_alpha1			8.8	1.2		Frk			13.1	2.6	
CK1_delta	3	0	6.6	8.3		GCK	8	71	1	55.2	69.8
CK1_epsilon1	3	75.3	7.3	79.2	44	GRK2	10	4	-9.6	0.4	
CK1_gamma1			1.9	1		GRK3	4	-1	1.1	0	
CK1_gamma2	10.5	6.3	18.3	2.3	-1.5	GRK5			2.5	0.9	
CK2_alpha1	4	6.7	5.2	4.3	-3.5	GRK6			11.7	3.2	
CLK1			11.3	2.6		GSK3_alpha	51.5	1	9.7	4.8	40.6
CLK2			0	21		GSK3_beta	77	-1	4.6	-6.1	11
CLK3			8.9	5.7		HIPK1			1.7	4.5	
CLK4				-1.3		HIPK2			2.8	6.8	40.0
CSF1R	8.4	97	2.5	37.5	85.7	HIPK4	42	11	5	11.1	18.6
CSK			9.8	17.9		Hyl	0.5	0.7	6.6	4.6	
CaMKI			0.0	17.4		IGF1R	9.5	9.7	2.9	5.9	6.5
CaMKII beta			11.7	4.8		IKK_alpha	-6	-2		9.2	2.2
CaMKI_delta			6.9	42.7		IKK_beta	2.5	1.6	6.5	-0.1	3.3
CamKII_alpha			-13.8	3.2		IKK_epsilon			6	-0.6	
				16.4		IRAK1			4.0	23.7	
CamKIV	20.2	22	-6.6		10.0	IRAK4		40	4.3	26.8	4
Cot	20.3	22	2.8	43.8	19.6	IRR	14	13	7.4	7.3	14.5
DAPK1				-11.3		InsR	7	7	3.5	1.3	

Detailed kinase selectivity data of compounds 5, 7, 13, 25, and 28 (2 of 3); Source: Invitrogen.

Compound	5	7	13	25	28	Compound	5	7	13	25	28
Test concentration [uM]	1	1	0.1	1	0.1	Test concentration [uM]		1	0.1	1	0.1
Itk	23	7	4		-1.4 PAK1		95	103	2.1	99.7	97.5
JAK1	2	-2	0.1				85.5	98	14.9	104	97.7
JAK2	9.4	39.3	3.4	-1.8			86	91.8	3.3	96.1	92.6
JAK3	9	39.7	-1.3	-4.3			98.5	16	89.5	5.1	29.2
JNK1_alpha1	9	57.7	4.1	58.5			100	20.3	75.1	8.2	28.5
JNK2	-1.5	13.7	-1	33.9	14.8	PAK6	99.6	24.3	49.9	22.2	21.8
JNK3	5.5	15.3	2.7	31.5	2.3	PASK	55.5	21.0	15.9	3.2	21.0
KDR	20	94.3	-3.1	14.7	72.2	PDGFR_alpha	2	76	-3.5	7.8	66.9
KHS1	55	106	-5.1	102	105	PDGFR_alpha(V561D)	23	98	55	14.9	96
Kit	7	68	-5.5	3.4	37	PDGFR_beta	14	57	0.7	2	
LIMK1	-5	93.5	00	40.5	42.4	PDK1(direct)	80.3	43.3	13.7	7	-6
LRRK2	16.8	48		-6.9	48.2	PI3K-A	-5	6		-3.5	
LTK			-0.9	-1.8		PI3K-G	-10.5	14.7		-5.2	4.1
Lck	46.5	103	7.6	85.8	97.5	PI3KC2b	8	19		2	
Lyn	76	98	-2.7	35.2	97.5	PI3K-D			-4.8		
LynB	79	101	11.1	34	99.8	PIM1	6	2	3.8	-1.4	-2
MAP4K4	17.1	101	14.6	58.7	104	PIM2	4	0	8.4	3	
MAPKAPK2	3	2	3.9	-3.8	107	PKA	103	2	-2.6	1.6	13
MAPKAPK3		-	4.8	-0.4		PKC_alpha	78	11.5	-12.8	21.4	11.4
MARK1	88.6	12.5	11.3	19.3	25.8	PKC_beta1	58	2	0.5	12.5	11.4
MARK3	100	15	5.5	19.6	37	PKC_delta	30		8.3	13.7	
MEK1	36.5	29	2.5	24.4	23.8	PKC_epsilon	62	11	-13.2	18.7	
MEK2	20	73	-0.6	15	23.0	PKC_eta	02	- ' '	12.3	14.3	
MEK3	20	13	-0.0	17		PKC_theta	97	2	22.8	20.1	17
MEKK2				32.7		PKC_zeta	- 57	- 2	16.4	22.9	17
MELK			4.1	47.1		PKD1	94	71.5	9.3	78.7	49.5
MKK6			-11.4	7.1		PKG1_alpha	34	7 1.5	-2	-1.5	49.5
MKNK1			-2.7	-4		PLK1	35	2	10.8	4.3	
MKNK2			-2.1	36.7		PLK2	30		9.2	4.3	
MLK1	53	86	15.4	9.2	11.4	PLK3	18.5	-7.3	5	-4.4	-5.8
MLK2	53	00	15.4	14.8	11.4	PRAK	16.5	-1.3	-2.3	5.2	-0.6
MRCK_alpha			-2.4	8.6		PRK1	68	5	10.6	11.5	-1.6
MSK1			4.2	15.6		PRKAA1	101	32.7	12.5	8.5	16
MSSK1			9.8	7.1		PRKAA1	100	55	12.5	17	8.3
	88	33.5		30	62.7			13	2.0	4.7	-4.8
MST1	88	33.5	-5.1		63.7	PhK_gamma1	95.9	13	3.2		-4.8
MST2	404	24.2	8.8	17 100	70.0	PhK_gamma2			17.3	7.7	
MST3	101	31.3	5.9		70.2	PrKX	00.5	62.2	5.3	15.6	40.4
MST4	96	19	-1.5	96	82	RAF1(Y340D,Y341D)	22.5	63.3	7.6	10.4	18.4
MYLK(smMLCK)	20	50.0	0.0	8.3	05.5	RIPK2	4.5	99	0.0	59.5	101
MYLK2(skMLCK)	30	50.8	8.2	28	25.5	ROCK1	5	-1	0.8	-1.4	
MYLK3(caMLCK)	-00	70.5	0.0	1.7	50.0	ROCK2	10	2	0.5	5.8	00.4
Mer	92	72.5	2.6	26.1	53.8	Ret	81	98	4.4	7	92.1
Met	19	61	4.4	31.8	13.3	Ron	8	79	0.3	49.2	6
Mink1	5.2	89.8	-2.8	65.7	97	Ros			6.8	6.2	
MuSK	_	_	0.3	16.9	4 -	Rse			1.4	47.5	
NEK1	2	9	8.1	4.2	1.5	Rsk1	4.5.5		6.7	15.4	
NEK2	8	72	6.3	10		Rsk2	105	6	11.7	9.2	-6
NEK4			2	3.8		Rsk3	101	15.5	14.9	25.6	11.9
NEK6			9.9	7.7		Rsk4	100	10.5	2.4	8.6	19.5
NEK9	11	4.5	1.6	1.6	-0.9	SGK1			4.4	-1.3	
NIK			-0.5			SGK2		_	-2.9	18	
NLK	12.2	77.9		44.6	5	SGK3	47	3	9.3	17.6	2.2

Detailed kinase selectivity data of compounds 5, 7, 13, 25, and 28 (3 of 3); Source: Invitrogen.

Compound	5	7	13	25	28
Test concentration [uM]	1	1	0.1	1	0.1
SIK2	68	98.3	0.8	88.7	96.3
SLK				9.3	
SPHK1	4	4		2.8	
SRPK1			5.4	4.1	
STK16				27.5	
STK33				18.1	
Src	87.6	94.3	1.9	26.5	92.9
Srm			11.1	-7.7	
Syk	15.1	53.3	4.3	1.6	37.1
TAK1-TAB1	38.2	15.5	-11	0.2	27.9
TAO1	5.5	98.5	-0.2	81	91.5
TBK1	45	34	11.6	5.3	4.3
TEC				2.9	
TGFBR1	-1	95.5		3.1	99.3
TNK2				1.4	
TSSK1	90	10	6.2	9.6	28
ΠK				12.6	
TXK			5.1	5.5	
TYK2	14	47	3.3	4.8	
Tie2	0	96	2.1	80.8	24.8
TrkA	83.7	91	9	25.5	51.6
TrkB			15.1	6.9	
WEE1				-1.2	
WNK2				43.6	
YSK1	97	9.8	6.5	96.3	63.9
Yes	86	99	-1.4	14.6	98
ZAK				15.1	
ZAP-70	10	9	2.4	3	4.5
ZIPK			2.9	3.9	
eEF-2K			4.3	10.3	
mTOR	-3	-8	-2.4	-0.5	
p38_alpha(direct)	7	13.3	4.4	-2.6	34.8
p38_beta	8	10	-6.4	5.6	
p38_delta	13	0	8.4	9.6	5.1
p38_gamma			8.1	14.2	
p70S6K	79.2	2	7.2	7.5	15.3